关注
Clement Chung
Clement Chung
Hematology oncology clinical pharmacy specialist
在 houstonmethodist.org 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and …
C Chung, M Christianson
Journal of oncology pharmacy practice 20 (1), 11-28, 2014
792014
Development and implementation of an interdisciplinary oncology program in a community hospital
C Chung, A Collins, N Cui
American Journal of Health-System Pharmacy 68 (18), 1740-1747, 2011
462011
Implementation of an integrated computerized prescriber order-entry system for chemotherapy in a multisite safety-net health system
C Chung, S Patel, R Lee, L Fu, S Reilly, T Ho, J Lionetti, MD George, ...
The Bulletin of the American Society of Hospital Pharmacists 75 (6), 398-406, 2018
442018
Restoring the switch for cancer cell death: Targeting the apoptosis signaling pathway
C Chung
The Bulletin of the American Society of Hospital Pharmacists 75 (13), 945-952, 2018
432018
Role of immunotherapy in targeting the bone marrow microenvironment in multiple myeloma: an evolving therapeutic strategy
C Chung
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (1 …, 2017
372017
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
C Chung
Journal of Oncology Pharmacy Practice 22 (3), 461-476, 2016
362016
Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer
C Chung, N Pherwani
American journal of health-system pharmacy 70 (21), 1887-1896, 2013
342013
Current targeted therapies in lymphomas
C Chung
American Journal of Health-System Pharmacy 76 (22), 1825-1834, 2019
262019
Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma
C Chung, S Reilly
American Journal of Health-System Pharmacy 72 (2), 101-110, 2015
232015
Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer
C Chung, MSH Lam
American journal of health-system pharmacy 70 (18), 1579-1587, 2013
232013
Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia
C Chung, R Lee
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34 (12 …, 2014
202014
From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer
C Chung
American Journal of Health-System Pharmacy 77 (24), 2064-2073, 2020
182020
Driving toward precision medicine for acute leukemias: are we there yet?
C Chung, H Ma
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (9 …, 2017
182017
Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation
C Chung
J Oncol Pharm Practice, https://doi.org/10.1177/1078155221100552, 2021
162021
Management of neuroendocrine tumors
C Chung
American Journal of Health-System Pharmacy 73 (21), 1729-1744, 2016
162016
To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade
C Chung
Journal of Oncology Pharmacy Practice 25 (3), 663-673, 2019
132019
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly (adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis
C Chung, R Lee
Journal of Oncology Pharmacy Practice 23 (6), 454-469, 2017
132017
Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia
C Chung
American journal of health-system pharmacy 71 (4), 279-288, 2014
122014
Targeting the androgen receptor signaling pathway in advanced prostate cancer
C Chung, K Abboud
American Journal of Health-System Pharmacy 79 (15), 1224-1235, 2022
102022
New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab
C Chung
Annals of Pharmacotherapy, 2020
72020
系统目前无法执行此操作,请稍后再试。
文章 1–20